It may be helpful to use a form of chemosensitivity testing, which is based upon the measurement of actual cancer cell death, as a method to match a cancer patient to a potential drug or drug combination.
Here is a contact email for Dr. Andrew Bosanquet, Bath. Dr. Bosanquet has a list of labs in Europe.
agb.scientist@gmail.com
Here is a contact email for Dr. Ian Cree, Queen Alexandra Hospital. He does the ATP cell-death assay.
ian.cree@porthosp.nhs.uk
You can also ship tumor specimens via FedEx or World Courier to any of the labs in the United States.
http://www.rationaltherapeutics.com/default.aspx
http://weisenthalcancer.com/Contact_Us.html
It would be enlightening to see a future prospective, randomized ovarian cancer clinical trial in which enrolled women are provided with treatment after assignment to one of three clinical trial arms:
(1) treatment based upon the standard of care (e.g., paclitaxel and carboplatin),
(2) treatment based upon molecular profiling, or
(3) treatment based upon chemosensitivity testing.
This type of study may uncover additional ovarian cancer treatment insights, both molecular and functional.
Newer forms of assays are being provided by private U.S. companies such as Precision Therapeutics (ChemoFx and BioSpeciFx assays), Rational Therapeutics (EVA-PCD and TARxGET assays), DiaTech Oncology (the MiCK "microculture kinetic" assay), and the Weisenthal Cancer Group (CytoRx, EGFRx and AngioRx assays).
Threaded Mode